# reload+after+2024-01-20 20:45:47.726923
address1§3545 John Hopkins Court
address2§Suite 250
city§San Diego
state§CA
zip§92121
country§United States
phone§858 731 8389
fax§858 731 8394
website§https://www.atyrpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
fullTimeEmployees§65
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Sanjay S. Shukla M.D., M.S.', 'age': 51, 'title': 'President, CEO & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 795479, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jill M. Broadfoot', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 556617, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nancy E. Denyes Krueger', 'age': 55, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 532135, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Xiang-Lei  Yang Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ashlee  Dunston', 'title': 'Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Villiger', 'title': 'Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Danielle  Campbell', 'title': 'VP of Human Resource', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Leslie  Nangle Ph.D.', 'title': 'Vice President of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ying J. Buechler Ph.D.', 'title': 'Executive Director of Biologics Development & Manufacturing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David J. King Ph.D.', 'age': 64, 'title': 'Scientific Consultant', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 327312, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.179
priceToSalesTrailing12Months§8.179546
currency§USD
dateShortInterest§1702598400
forwardEps§-0.85
pegRatio§-0.12
exchange§NCM
quoteType§EQUITY
shortName§aTyr Pharma, Inc.
longName§aTyr Pharma, Inc.
firstTradeDateEpochUtc§1431005400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§5ecda69d-e560-3873-96f0-ba688675083a
gmtOffSetMilliseconds§-18000000
targetHighPrice§35.0
targetLowPrice§12.0
targetMeanPrice§23.2
targetMedianPrice§20.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§8.091
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
